Mexiletine nonclinical toxicology

Revision as of 17:17, 10 March 2014 by ShiSheng (talk | contribs) (Created page with "__NOTOC__ {{Mexiletine}} {{CMG}}; {{AE}} {{SS}} ==Nonclinical Toxicology== Carcinogenesis, Mutagenesis, Impairment of Fertility Studies of carcinogenesis in rats (24 months...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Mexiletine
MEXILETINE HYDROCHLORIDE® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
How Supplied/Storage and Handling
Labels and Packages
Clinical Trials on Mexiletine
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment of Fertility

Studies of carcinogenesis in rats (24 months) and mice (18 months) did not demonstrate any tumorigenic potential. Mexiletine was found to be non-mutagenic in the Ames test. Mexiletine did not impair fertility in the rat.[1]

References

  1. "MEXILETINE HYDROCHLORIDE CAPSULE [TEVA PHARMACEUTICALS USA INC]". Retrieved 3 March 2014.

Template:Antiarrhythmic agents